Atopic Dermatitis

Rook's Textbook of Dermatology: Eighth Edition

Volumn 1, Issue , 2010, Pages 1005-1038

  Friedmann, Peter S ^a   Ardern Jones, Michael R ^b   Holden, Colin A ^c  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

Author keywords

Atopic and non atopic dermatitis; Atopic dermatitis; Atopic dermatitis, difficult to define lacking diagnostic test and showing clinical features; Atopic hand eczema; Genetic influence genetic factors determining expression of atopic phenotype; IgE, main immunoglobulin abnormality; International study of asthma and allergies in childhood (ISAAC); Pathogenesis of eczema and role of allergy; Role of infection patients with atopic dermatitis, susceptible to cutaneous infections; Urticaria cannot be shown to be due to IgE or any allergic sensitivity

Indexed keywords

EID: 84888763534     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444317633.ch24     Document Type: Chapter

References (523)

1. Darsow U, Lubbe J, Taïeb A et al., for the European Task Force on Atopic Dermatitis. Position paper on the diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-95.
2. Williams H. Atopic dermatitis. N Engl J Med 2005; 352: 2314-24.
3. Brown S, Reynolds NJ. Atopic and non-atopic eczema. BMJ 2006; 332: 584-8.
4. Juhlin L, Johanson SGO, Bennich H et al. Immunoglobulin E in dermatoses. Arch Dermatol 1969; 100: 12-6.
5. Schmid-Grendelmeier P, Simon D, Simon HU et al. Epidemiology, clinical features, and immunology of the intrinsic (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56: 841-9.
6. Park J-H, Choi Y-L, Namkung J-H et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol 2006; 155: 778-83.
7. Fölster-Holst R, Pape M, Buss YL et al. Low prevalence of the intrinsic form of atopic dermatitis among adult patients. Allergy 2006; 61: 629-32.
8. Johannson SGO, Bieber T, Dahl R et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
9. Hanifin JM, Rajka RG. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92 (Suppl. 144): 44-7.
10. Schultz-Larsen F, Hanifin JM. Secular changes in the occurrence of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 176: 7-12.
11. Williams HC, Burney PGJ, Pembroke AC, Hay RJ. The U.K. working party's diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406-16.
12. Williams HC, Burney PGJ, Pembroke AC, Hay RJ. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. Br J Dermatol 1996; 135: 12-17.
13. Bos JD, Van Leent EJ, Sillevis Smitt JH. The millennium criteria for the diagnosis of atopic dermatitis. Exp Dermatol 1998; 7: 132-8.
14. Eichenfield LF, Hanifin JM, Luger TA et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003; 49: 1088-95.
15. McNally N, Phillips D. Geographical studies of atopic dermatitis. In: Williams HC, ed. Atopic Dermatitis: The Epidemiology, Causes and Prevention of Atopic Dermatitus. Cambridge: Cambridge University Press, 2000: 71-84.
16. Williams HC. Epidemiology of atopic dermatitis: recent advances and future predictions. Curr Probl Dermatol 1999; 28: 9-17.
17. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225-32.
18. Selnes A, Bolle R, Lund E, Holt J. Cumulative incidence of asthma and allergy in north-Norwegian schoolchildren in 1985 and 1995. Pediatr Allergy Immunol 2002; 13: 58-63.
19. Schultz Larsen FV, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34: 760-4.
20. Williams HC, Pembroke AC, Forsdyke H et al. London-born black Caribbean children are at increased risk of atopic dermatitis. J Am Acad Dermatol 1995; 32: 212-7.
21. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994; 30: 35-9.
22. Okuma M. [Prevalence rate of allergic diseases among school children in Okinawa]. Arerugi 1994; 43: 492-500.
23. Sugiura H, Uchiyama M, Omoto M et al. Prevalence of infantile and early childhood eczema in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol 1997; 77: 52-3.
24. Henderson CA. The prevalence of atopic eczema in two different villages in rural Tanzania. Br J Dermatol 1995; 133 (Suppl. 45): 50.
25. Waite DA, Eyles EF, Tonkin SL, O'Donnell TV. Asthma prevalence in Tokelauan children in two environments. Clin Allergy 1980; 10: 71-5.
26. Kalyoncu AF, Stalenheim G. Survey on the allergic status in a Turkish population in Sweden. Allergol Immunopathol (Madr) 1993; 21: 11-4.
27. Diepgen T. Is the prevalence of atopic dermatitis increasing? In: Williams HC, ed. Atopic Dermatitis: The Epidemiology, Causes and Prevention of Atopic Dermatitis. Cambridge: Cambridge University Press, 2000: 96-109.
28. Schultz Larsen FV, Holm NV, Henningsen K. Atopic dermatitis: a geneticepidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986; 15: 487-94.
29. Schultz Larsen FV. Atopic dermatitis: a genetic-epidemiologic study in a population- based twin sample. J Am Acad Dermatol 1993; 28: 719-23.
30. Herd RM, Tidman MJ, Prescott RJ, Hunter JA. The cost of atopic eczema. Br J Dermatol 1996; 135: 20-3.
31. Ellis CN, Drake LA, Prendergast MM et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46: 361-70.
32. Schultz Larsen FV, Holm NV. Atopic dermatitis in a population based twin series. Concordance rates and heritability estimation. Acta Derm Venereol Suppl (Stockh) 1985; 114: 159-63.
33. Schultz Larsen FV, Holm NV, Henningsen K. Atopic dermatitis: a geneticepidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986; 15: 487-94.
34. Schultz Larsen FV. The epidemiology of atopic dermatitis. Monogr Allergy 1993; 31: 9-28.
35. Lee YA, Wahn U, Kehrt R et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet 2000; 26: 470-3.
36. Cookson WO, Ubhi B, Lawrence R et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001; 27: 372-3.
37. Bradley M, Soderhall C, Luthman H et al. Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum Mol Genet 2002; 11: 1539-48.
38. Haagerup A, Bjerke T, Schiotz PO et al. Atopic dermatitis-a total genome-scan for susceptibility genes. Acta Derm Venereol 2004; 84: 346-52.
39. Zhang Y, Leaves NI, Anderson GG et al. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat Genet 2003; 34: 181-6.
40. Sandford AJ, Shirakawa T, Moffatt MF et al. Localisation of atopy and beta subunit of high-affinity IgE receptor (Fc epsilon RI) on chromosome 11q [see comments]. Lancet 1993; 341: 332-4.
41. Doull IJ, Lawrence S, Watson M et al. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Am J Respir Crit Care Med 1996; 153: 1280-4.
42. He JQ, Chan-Yeung M, Becker AB et al. Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children. Genes Immun 2003; 4: 385-9.
43. Kawashima T, Noguchi E, Arinami T et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 1998; 35: 502-4.
44. Hosomi N, Fukai K, Oiso N et al. Polymorphisms in the promoter of the interleukin-4 receptor alpha chain gene are associated with atopic dermatitis in Japan. J Invest Dermatol 2004; 122: 843-5.
45. Oiso N, Fukai K, Ishii M. Interleukin 4 receptor alpha chain polymorphism Gln551Arg is associated with adult atopic dermatitis in Japan. Br J Dermatol 2000; 142: 1003-6.
46. Deichmann KA, Heinzmann A, Forster J et al. Linkage and allelic association of atopy and markers flanking the IL4-receptor gene. Clin Exp Allergy 1998; 28: 151-5.
47. Hershey GK, Friedrich MF, Esswein LA et al. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997; 337: 1720-5.
48. Kruse S, Japha T, Tedner M et al. The polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene are associated with atopy and influence the signal transduction. Immunology 1999; 96: 365-71.
49. Mao XQ, Shirakawa T, Yoshikawa T et al. Association between genetic variants of mast-cell chymase and eczema. Lancet 1996; 348: 581-3.
50. Tanaka K, Sugiura H, Uehara M et al. Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Clin Exp Allergy 1999; 29: 800-3.
51. Kawashima T, Noguchi E, Arinami T et al. No evidence for an association between a variant of the mast cell chymase gene and atopic dermatitis based on case-control and haplotype-relative-risk analyses. Hum Hered 1998; 48: 271-4.
52. Pascale E, Tarani L, Meglio P et al. Absence of association between a variant of the mast cell chymase gene and atopic dermatitis in an Italian population. Hum Hered 2001; 51: 177-9.
53. Nickel RG, Casolaro V, Wahn U et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000; 164: 1612-6.
54. Bai B, Tanaka K, Tazawa T et al. Association between RANTES promoter polymorphism-401A and enhanced RANTES production in atopic dermatitis patients. J Dermatol Sci 2005; 39: 189-91.
55. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
56. Stemmler S, Parwez Q, Petrasch-Parwez E et al. Two common loss-of-function mutations within the filaggrin gene predispose for early onset of atopic dermatitis. J Invest Dermatol 2007; 127: 722-4.
57. Barker JN, Palmer CN, Zhao Y et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol 2007; 127: 564-7.
58. Palmer CN, Ismail T, Lee SP et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007; 120: 64-8.
59. Walley AJ, Chavanas S, Moffatt MF et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001; 29: 175-8.
60. Kato A, Fukai K, Oiso N et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003; 148: 665-9.
61. Nishio Y, Noguchi E, Shibasaki M et al. Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. Genes Immun 2003; 4: 515-7.
62. Dold S, Wjst M, von Mutius E et al. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Child 1992; 67: 1018-22.
63. Ruiz RG, Kemeny DM, Price JF. Higher risk of infantile atopic dermatitis from maternal atopy than from paternal atopy. Clin Exp Allergy 1992; 22: 762-6.
64. Cookson WO, Young RP, Sandford AJ et al. Maternal inheritance of atopic IgE responsiveness on chromosome 11q [published erratum appears in Lancet 1992 Oct 31; 340(8827): 1110]. Lancet 1992; 340: 381-4.
65. Selnes A, Bolle R, Lund E et al. Cumulative incidence of asthma and allergy in north-Norwegian schoolchildren in 1985 and 1995. Pediatr Allergy Immunol 2002; 13: 58-63.
66. Barker DJ. Fetal origins of coronary heart disease. BMJ 1995; 311: 171-4.
67. Peters TJ, Golding J. The epidemiology of childhood eczema: II. Statistical analyses to identify independent early predictors. Paediatr Perinat Epidemiol 1987; 1: 80-94.
68. Olesen AB, Ellingsen AR, Olesen H et al. Atopic dermatitis and birth factors: historical follow up by record linkage. BMJ 1997; 314: 1003-8.
69. Godfrey K. Fetal and perinatal origins of atopic dermatitis. In: Williams HC, ed. Atopic Dermatitis: The Epidemiology, Causes and Prevention of Atopic Dermatitis. Cambridge: Cambridge University Press, 2000: 125-38.
70. Tariq SM, Arshad SH, Matthews SM et al. Elevated cord serum IgE increases the risk of aeroallergen sensitization without increasing respiratory allergic symptoms in early childhood. Clin Exp Allergy 1999; 29: 1042-8.
71. Schafer T, Vieluf D, Behrendt H et al. Atopic eczema and other manifestations of atopy: results of a study in East and West Germany. Allergy 1996; 51: 532-9.
72. von Mutius E, Fritzsch C, Weiland SK et al. Prevalence of asthma and allergic disorders among children in united Germany: a descriptive comparison. BMJ 1992; 305: 1395-9.
73. Yemaneberhan H, Flohr C, Lewis SA et al. Prevalence and associated factors of atopic dermatitis symptoms in rural and urban Ethiopia. Clin Exp Allergy 2004; 34: 779-85.
74. Strachan DP. Family size, infection and atopy: the first decade of the 'hygiene hypothesis'. Thorax 2000; 55 (Suppl. 1): S2-10.
75. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-60.
76. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005; 25 (Suppl.): 74-80.
77. Benn CS, Melbye M, Wohlfahrt J et al. Cohort study of sibling effect, infectious diseases, and risk of atopic dermatitis during first 18 months of life. BMJ 2004; 328: 1223.
78. McKeever TM, Lewis SA, Smith C et al. Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. J Allergy Clin Immunol 2002; 109: 43-50.
79. Bodner C, Godden D, Seaton A. Family size, childhood infections and atopic diseases. The Aberdeen WHEASE Group. Thorax 1998; 53: 28-32.
80. Linneberg A, Ostergaard C, Tvede M et al. IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. J Allergy Clin Immunol 2003; 111: 847-53.
81. Wickens KL, Crane J, Kemp TJ et al. Family size, infections, and asthma prevalence in New Zealand children. Epidemiology 1999; 10: 699-705.
82. Forastiere F, Agabiti N, Corbo GM et al. Socioeconomic status, number of siblings, and respiratory infections in early life as determinants of atopy in children. Epidemiology 1997; 8: 566-70.
83. Nafstad P, Magnus P, Jaakkola JJ. Early respiratory infections and childhood asthma. Pediatrics 2000; 106: E38.
84. Matricardi PM, Rosmini F, Ferrigno L et al. Cross-sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. BMJ 1997; 314: 999-1003.
85. Ponsonby AL, Couper D, Dwyer T et al. Relationship between early life respiratory illness, family size over time, and the development of asthma and hay fever: a seven year follow-up study. Thorax 1999; 54: 664-9.
86. Matricardi PM, Rosmini F, Riondino S et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000; 320: 412-7.
87. von Ehrenstein OS, von Mutius E, Illi S et al. Reduced risk of hay fever and asthma among children of farmers. Clin Exp Allergy 2000; 30: 187-93.
88. Braun-Fahrlander C. The role of the farm environment and animal contact for the development of asthma and allergies. Clin Exp Allergy 2001; 31: 1799-803.
89. Braun-Fahrlander C, Riedler J, Herz U et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002; 347: 869-77.
90. Riedler J, Eder W, Oberfeld G et al. Austrian children living on a farm have less hay fever, asthma and allergic sensitization. Clin Exp Allergy 2000; 30: 194-200.
91. von Mutius E, Braun-Fahrlander C, Schierl R et al. Exposure to endotoxin or other bacterial components might protect against the development of atopy. Clin Exp Allergy 2000; 30: 1230-4.
92. Warner JO, Warner JA, Miles EA et al. Reduced interferon-gamma secretion in neonates and subsequent atopy. Lancet 1994; 344: 1516.
93. Lange J, Ngoumou G, Berkenheide S et al. High interleukin-13 production by phytohaemagglutinin- and Der p 1-stimulated cord blood mononuclear cells is associated with the subsequent development of atopic dermatitis at the age of 3 years. Clin Exp Allergy 2003; 33: 1537-43.
94. Grewe M, Walther S, Gyufko K et al. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 1995; 105: 407-10.
95. Thepen T, Langeveld-Wildschut EG, Bihari IC et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996; 97: 828-37.
96. Zachary CB, Allen MH, MacDonald DM. In situ quantification of T-lymphocyte subsets and Langerhans cells in the inflammatory infiltrate of atopic eczema. Br J Dermatol 1985; 112: 149-56.
97. Lever R, Turbitt M, Sanderson A et al. Immunophenotyping of the cutaneous infiltrate and of the mononuclear cells in the peripheral blood in patients with atopic dermatitis. J Invest Dermatol 1987; 89: 4-7.
98. Bos JD, Hagenaars C, Das PK et al. Predominance of 'memory' T cells (CD4+, CDw29+) over 'naive' T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989; 281: 24-30.
99. Leung DY, Bhan AK, Schneeberger EE et al. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 1983; 71: 47-56.
100. Piletta PA, Wirth S, Hommel L et al. Circulating skin-homing T cells in atopic dermatitis. Selective up-regulation of HLA-DR, interleukin-2R, and CD30 and decrease after combined UV-A and UV-B phototherapy. Arch Dermatol 1996; 132: 1171-6.
101. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94: 870-6.
102. Hamid Q, Naseer T, Minshall EM et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996; 98: 225-31.
103. Wierenga EA, Snoek M, de Groot C et al. Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients. J Immunol 1990; 144: 4651-6.
104. Parronchi P, Macchia D, Piccinni MP et al. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad Sci USA 1991; 88: 4538-42.
105. Hamid Q, Azzawi M, Ying S et al. Interleukin-5 mRNA in mucosal bronchial biopsies from asthmatic subjects. Int Arch Allergy Appl Immunol 1991; 94: 169-70.
106. van der Heijden FL, Wierenga EA, Bos JD et al. High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991; 97: 389-94.
107. Del Prete GF, de Carli M, D'Elios MM et al. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23: 1445-9.
108. Secrist H, Chelen CJ, Wen Y et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993; 178: 2123-30.
109. Varney VA, Hamid QA, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92: 644-51.
110. McHugh SM, Deighton J, Stewart AG et al. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25: 828-38.
111. Jutel M, Pichler WJ, Skrbic D et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergenstimulated T cell cultures. J Immunol 1995; 154: 4187-94.
112. Agosti JM, Sprenger JD, Lum LG et al. Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. N Engl J Med 1988; 319: 1623-8.
113. Saurat JH. Eczema in primary immune-deficiencies. Clues to the pathogenesis of atopic dermatitis with special reference to the Wiskott-Aldrich syndrome. Acta Derm Venereol Suppl (Stockh) 1985; 114: 125-8.
114. Koharazawa H, Kanamori H, Takabayashi M et al. Resolution of atopic dermatitis following allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transpl 2005; 35: 1223-4.
115. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic-dermatitis. J Invest Dermatol 1995; 105: S84-S88.
116. Kanda N, Watanabe S. Intracellular 3',5'-adenosine cyclic monophosphate level regulates house dust mite-induced interleukin-13 production by T cells from mite-sensitive patients with atopic dermatitis. J Invest Dermatol 2001; 116: 3-11.
117. Chen Y, Kuchroo VK, Inobe J et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-40.
118. Powrie F, Correa-Oliveira R, Mauze S et al. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994; 179: 589-600.
119. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-42.
120. Bacchetta R, Passerini L, Gambineri E et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116: 1713-22.
121. Akdis CA, Blesken T, Akdis M et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106.
122. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33: 1205-14.
123. Bellinghausen I, Konig B, Bottcher I et al. Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor. Immunology 2005; 116: 103-11.
124. Ling EM, Smith T, Nguyen XD et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363: 608-15.
125. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 2004; 199: 1679-88.
126. Cavani A, Nasorri F, Ottaviani C et al. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 2003; 171: 5760-8.
127. Karagiannidis C, Akdis M, Holopainen P et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114: 1425-33.
128. Peek EJ, Richards DF, Faith A et al. Interleukin-10-secreting 'regulatory' T cells induced by glucocorticoids and beta2-agonists. Am J Respir Cell Mol Biol 2005; 33: 105-11.
129. Ou LS, Goleva E, Hall C et al. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004; 113: 756-63.
130. Loser K, Mehling A, Loeser S et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12: 1372-9.
131. Maggi L, Santarlasci V, Liotta F et al. Demonstration of circulating allergenspecific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol 2007; 120: 429-36.
132. Vukmanovic-Stejic M, McQuaid A, Birch KE et al. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. Br J Dermatol 2005; 153: 750-7.
133. Verhagen J, Akdis M, Traidl-Hoffmann C et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006; 117: 176-83.
134. Ohman S, Johansson SG. Allergen-specific IgE in atopic dermatitis. Acta Derm Venereol 1974; 54: 283-90.
135. Ohman S, Johansson SG. Immunoglobulins in atopic dermatitis with special reference to IgE. Acta Derm Venereol 1974; 54: 193-202.
136. Jones HE, Inouye JC, McGerity JL et al. Atopic disease and serum immunoglobulin-E. Br J Dermatol 1975; 92: 17-25.
137. Uehara M, Sawai T. Familial background of respiratory atopy. A factor of type I allergy to house dust mite in patients with atopic dermatitis. Arch Dermatol 1989; 125: 939-43.
138. Wuthrich B, Schnyder UW. Haufigkeit genetische Aspekte und Prognose der Neurodermatitis atopica. Allergologie 1991; 14: 284-90.
139. Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Paediatr 1985; 107: 669-75.
140. Guillet G, Guillet MH. Food allergy in dermatological disease in children. Revue Francaise D Allergologie Et D Immunologie Clinique 1997; 37: 602-12.
141. Uehara M, Kimura C, Uenishi T. Type I allergy to foods in atopic dermatitis. Comparison between RAST-positive and RAST-negative cases. Acta Derm Venereol Suppl (Stockh) 1992; 176: 38-40.
142. Adinoff AD, Tellez P, Clark RA. Atopic dermatitis and aeroallergen contact sensitivity. J Allergy Clin Immunol 1988; 81: 736-42.
143. Beck HI, Korsgaard J. Atopic dermatitis and house dust mites. Br J Dermatol 1989; 120: 245-51.
144. van der Heijden FL, Joost van Neerven RJ, van Katwijk M et al. Serum-IgEfacilitated allergen presentation in atopic disease. J Immunol 1993; 150: 3643-50.
145. Bieber T. Fc epsilon RI on human epidermal Langerhans cells: an old receptor with new structure and functions. Int Arch Allergy Immunol 1997; 113: 30-4.
146. Johansson SG, Juhlin L. Immunoglobulin E in 'healed' atopic dermatitis and after treatment with corticosteroids and azathioprine. Br J Dermatol 1970; 82: 10-3.
147. Nordvall SL, Lindgren L, Johansson SG et al. IgE antibodies to Pityrosporum orbiculare and Staphylococcus aureus in patients with very high serum total IgE. Clin Exp Allergy 1992; 22: 756-61.
148. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248: 705-11.
149. McFadden JP, Noble WC, Camp RD. Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol 1993; 128: 631-2.
150. Hofer MF, Lester MR, Schlievert PM et al. Upregulation of IgE synthesis by staphylococcal toxic shock syndrome toxin-1 in peripheral blood mononuclear cells from patients with atopic dermatitis. Clin Exp Allergy 1995; 25: 1218-27.
151. Kapp A, Kemper A, Schopf E et al. Detection of circulating immune complexes in patients with atopic dermatitis and psoriasis. Acta Derm Venereol 1986; 66: 121-6.
152. Czech W, Stadler BM, Schopf E et al. IgE autoantibodies in atopic dermatitis- occurrence of different antibodies against the CH3 and the CH4 epitopes of IgE. Allergy 1995; 50: 243-8.
153. Swainson JA, Wilson PB, Dore P et al. Evidence for circulating complexes containing IgE in patients with atopic dermatitis. Int Arch Allergy Appl Immunol 1985; 76: 237-42.
154. Johansson SG. Anti-IgE antibodies in human serum. J Allergy Clin Immunol 1986; 77: 555-7.
155. Williams RC Jr, Griffiths RW, Emmons JD et al. Naturally occurring human antiglobulins with specificity for E. J Clin Invest 1972; 51: 955-63.
156. Marone G, Casolaro V, Paganelli R et al. IgG anti-IgE from atopic dermatitis induces mediator release from basophils and mast cells. J Invest Dermatol 1989; 93: 246-52.
157. Paganelli R, Quinti I. Pathological significance of circulating IgG anti-IgE complexes. Monogr Allergy 1989; 26: 184-97.
158. Valenta R, Maurer D, Steiner R et al. Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol 1996; 107: 203-8.
159. Valenta R, Natter S, Seiberler S et al. Molecular characterization of an autoallergen, Homs 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol 1998; 111: 1178-83.
160. Cooper KD, Kazmierowski JA, Wuepper KD. Immunoregulation in atopic dermatitis. Functional analysis of T-B cell interactions and enumeration of Fc receptor-bearing T-cells. J Invest Dermatol 1983; 80: 139-45.
161. Barnetson R StC, Merrett TC. Food allergy and atopic eczema. Proc Nutr Soc 1983; 42: 247-56.
162. Merrett J, Barnetson R StC, Burr ML. Total and specific IgG4 antibody levels in atopic eczema. Clin Exp Immunol 1984; 56: 645-52.
163. Husby S, Larsen FS, Ahlstedt S. Humoral immunity to dietary antigens in atopic dermatitis. II. Analysis of IgE and IgG subclass antibodies. Allergy 1986; 41: 386-91.
164. Rowntree S, Platts-Mills TAB, Cogswell JJ. A subclass IgG4-specific antigen binding radioimmunoassay (RIA): comparison between IgG and IgG4 antibodies to food and inhaled antigens in adult atopic dermatitis after desensitization treatment and during development of antibody responses in children. J Allergy Clin Immunol 1987; 80: 622-30.
165. Gwynn CM, Morrison Smith J, Leon GL. Role of IgG4 subclass in childhood allergy. Lancet 1978; i: 910-1.
166. Gwynn CM, Morrison Smith J, Leon GL. IgE and IgG4 subclass in atopic families. Clin Allergy 1979; 9: 119-23.
167. Parish WE. The clinical relevance of heat-stable, short-term sensitizing anaphylactic IgG antibodies (IgG S-TS) and of related activities of IgG4 and IgG2. Br J Dermatol 1981; 105: 225-31.
168. Gondo A, Saeki N, Tokuda Y. IgG4 antibodies in patients with atopic dermatitis. Br J Dermatol 1987; 117: 301-10.
169. Contoli M, Message SD, Laza-Stanca V et al. Role of deficient type III interferonlambda production in asthma exacerbations. Nat Med 2006; 12: 1023-6.
170. Wark PA, Johnston SL, Bucchieri F et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201: 937-47.
171. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-60.
172. Nomura I, Goleva E, Howell MD et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171: 3262-9.
173. Howell MD, Boguniewicz M, Pastore S et al. Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol 2006; 121: 332-8.
174. Isolauri E, Turjanmaa K. Combined skin prick and patch testing enhances identification of food allergy in infants with atopic dermatitis. J Allergy Clin Immunol 1996; 97: 9-15.
175. Majamaa H, Seppala U, Palosuo T et al. Positive skin and oral challenge responses to potato and occurrence of immunoglobulin E antibodies to patatin (Solt 1) in infants with atopic dermatitis. Pediatr Allergy Immunol 2001; 12: 283-8.
176. Miles EA, Warner JA, Jones AC et al. Peripheral blood mononuclear cell proliferative responses in the first year of life in babies born to allergic parents. Clin Exp Allergy 1996; 26: 780-8.
177. Weidinger S, Illig T, Baurecht H et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006; 118: 214-9.
178. Palmer CN, Ismail T, Lee SP et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007; 120: 64-8.
179. Ng TW, Holt PG, Prescott SL. Cellular immune responses to ovalbumin and house dust mite in egg-allergic children. Allergy 2002; 57: 207-14.
180. Bjorksten F, Suoniemi I, Koski V. Neo-natal birch pollen contact and subsequent allergy to birch pollen. Clin Allergy 1980; 10: 585-91.
181. Warner JO, Price JF. House dust mite sensitivity in childhood asthma. Arch Dis Child 1978; 53: 710-3.
182. Arshad SH, Matthews S, Gant C et al. Effect of allergen avoidance on development of allergic disorders in infancy. Lancet 1992; 339: 1493-7.
183. Nishioka K, Yasueda H, Saito H. Preventive effect of bedding encasement with microfine fibers on mite sensitization. J Allergy Clin Immunol 1998; 101: 28-32.
184. Smith TF, Kelly LB, Heymann PW et al. Natural exposure and serum antibodies to house dust mite of mite allergic children with asthma in Atlanta. J Allergy Clin Immunol 1985; 76: 782-8.
185. Prescott SL, Macaubas C, Holt BJ et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J Immunol 1998; 160: 4730-7.
186. Prescott SL, Macaubas C, Smallacombe T et al. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999; 353: 196-200.
187. Munro CS, Higgins EM, Marks JM et al. Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br J Dermatol 1991; 124: 43-8.
188. Friedmann PS, Tan BB, Musaba E et al. Pathogenesis and management of atopic dermatitis. Clin Exp Allergy 1995; 25: 799-806.
189. van Voorst Vader PC, Lier JG, Woest TE et al. Patch tests with house dust mite antigens in atopic dermatitis patients: methodological problems. Acta Derm Venereol (Stockh) 1991; 71: 301-5.
190. Ring J, Darsow U, Gfesser M et al. The 'atopy patch test' in evaluating the role of aeroallergens in atopic eczema. Int Arch Allergy Immunol 1997; 113: 379-83.
191. Turjanmaa K. 'Atopy patch tests' in the diagnosis of delayed food hypersensitivity. Allerg Immunol (Paris) 2002; 34: 95-7.
192. Rokugo M, Tagami H, Usuba Y et al. Contact sensitivity to Pityrosporum ovale in patients with atopic dermatitis. Arch Dermatol 1990; 126: 627-32.
193. Tengvall LM, Johansson C, Scheynius A et al. Positive atopy patch test reactions to Pityrosporum orbiculare in atopic dermatitis patients. Clin Exp Allergy 2000; 30: 122-31.
194. Back O, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2001; 15: 34-8.
195. van der Heijden FL, Wierenga EA, Bos JD et al. High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991; 97: 389-94.
196. Bos JD, Wierenga EA, Sillevis Smitt JH et al. Immune dysregulation in atopic eczema. Arch Dermatol 1992; 128: 1509-12.
197. van Reijsen FC, Bruijnzeel-Koomen CA, Kalthoff FS et al. Skin-derived aeroallergen- specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992; 90: 184-93.
198. Kay AB, Ying S, Varney V et al. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colonystimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991; 173: 775-8.
199. Grewe M, Gyufko K, Schopf E et al. Lesional expression of interferon-gamma in atopic eczema. Lancet 1994; 343: 25-6.
200. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94: 870-6.
201. Tan BB, Weald D, Strickland I et al. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347: 15-8.
202. Gutgesell C, Heise S, Seubert S et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol 2001; 145: 70-4.
203. Terreehorst I, Duivenvoorden HJ, Tempels-Pavlica Z et al. The effect of encasings on quality of life in adult house dust mite allergic patients with rhinitis, asthma and/or atopic dermatitis. Allergy 2005; 60: 888-93.
204. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006; 144: 1-9.
205. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-60.
206. Nomura I, Goleva E, Howell MD et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171: 3262-9.
207. Bruch-Gerharz D, Fehsel K, Suschek C et al. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996; 184: 2007-12.
208. Rieg S, Steffen H, Seeber S et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol 2005; 174: 8003-10.
209. Imayama S, Shimozono Y, Hoashi M et al. Reduced secretion of IgA to skin surface of patients with atopic dermatitis. J Allergy Clin Immunol 1994; 94: 195-200.
210. Toshitani A, Imayama S, Shimozono Y et al. Reduced amount of secretory component of IgA secretion in tears of patients with atopic dermatitis. J Dermatol Sci 1999; 19: 134-8.
211. Guzik TJ, Bzowska M, Kasprowicz A et al. Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. Clin Exp Allergy 2005; 35: 448-55.
212. Zollner TM, Munk ME, Keller T et al. The superantigen exfoliative toxin induces cutaneous lymphocyte-associated antigen expression in peripheral human T lymphocytes. Immunol Lett 1996; 49: 111-6.
213. Bunikowski R, Mielke ME, Skarabis H et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 2000; 105: 814-9.
214. Zollner TM, Wichelhaus TA, Hartung A et al. Colonization with superantigenproducing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy 2000; 30: 994-1000.
215. Langer K, Breuer K, Kapp A et al. Staphylococcus aureus-derived enterotoxins enhance house dust mite-induced patch test reactions in atopic dermatitis. Exp Dermatol 2007; 16: 124-9.
216. Ardern-Jones MR, Black AP, Bateman EA et al. Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc Natl Acad Sci U S A 2007; 104: 5557-62.
217. Ou LS, Goleva E, Hall C et al. Tregulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004; 113: 756-63.
218. Li LB, Goleva E, Hall CF et al. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004; 114: 1059-69.
219. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000; 12; 114-21.
220. Swain SL. Helper T cell differentiation. Curr Opin Immunol 1999; 11: 180-5.
221. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-13.
222. Macatonia SE, Hosken NA, Litton M et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995; 154: 5071-9.
223. Langenkamp A, Messi M, Lanzavecchia A et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nature Immunol 2000; 1: 311-6.
224. Heufler C, Koch F, Stanzl U et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26: 659-68.
225. O'Garra A, Murphy K. Role of cytokines in development of Th1 and Th2 cells. Chem Immunol 1996; 63: 1-13.
226. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146: 108-13.
227. Ohmen JD, Hanifin JM, Nickoloff BJ et al. Overexpression of IL-l0 in atopic-dermatitis- contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 1995; 154: 1956-63.
228. D'Andrea A, Aste Amezaga M, Valiante NM et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8.
229. Bruijnzeel-Koomen CA, van Wichen DF, Toonstra J et al. The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 1986; 278: 199-205.
230. Mudde GC, van Reijsen FC, Bruijnzeel-Koomen CA. IgE-positive Langerhans cells and Th2 allergen-specific T cells in atopic dermatitis. J Invest Dermatol 1992; 99: 103S.
231. Bieber T, de la Salle H, Wollenberg A et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992; 175: 1285-90.
232. Wang B, Rieger A, Kilgus O et al. Epidermal Langerhans cells from normal human skin bind monomeric IgE via Fc epsilon RI. J Exp Med 1992; 175: 1353-65.
233. Bieber T, Kraft S, Jurgens M et al. New insights in the structure and biology of the high affinity receptor for IgE (Fc epsilon RI) on human epidermal Langerhans cells. J Dermatol Sci 1996; 13: 71-5.
234. Semper AE, Heron K, Woollard ACS et al. Surface expression of FcεRI on Langerhans' cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma, and rhinitis. J Allergy Clin Immunol 2003; 112: 411-9.
235. Jurgens M, Wollenberg A, Hanau D et al. Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon RI. J Immunol 1995; 155: 5184-9.
236. Mudde GC, van Reijsen FC, Boland GJ et al. Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. Immunol 1990; 69: 335-41.
237. Liu YJ, Soumelis V, Watanabe N et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 2007; 25: 193-219.
238. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006; 203: 269-73.
239. Ebner S, Nguyen VA, Forstner M et al. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007; 119: 982-90.
240. Lobitz WC, Campbell CJ. Physiologic studies in atopic dermatitis (disseminated neurodermatitis). I. Local cutaneous response to intradermally injected acetylcholine and epinephrine. Arch Dermatol Syphilol 1953; 67: 575-89.
241. West JR, Johnson LA, Winkelmann RK. Delayed blanch phenomenon in atopic individuals without dermatitis. Arch Dermatol 1962; 85: 227-31.
242. Champion RA. Abnormal vascular reactions in atopic eczema. Br J Dermatol 1963; 75: 12-5.
243. Szentivanyi A. The beta adrenergic theory of the atopic abnormality in bronchial asthma. J Allergy Clin Immunol 1968; 42: 203-32.
244. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic-dermatitis. J Invest Dermatol 1995; 105: S84-8.
245. Chan SC, Kim JW, Henderson WR Jr et al. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 1993; 151: 3345-52.
246. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146: 108-13.
247. Hanifin JM, Chan SC, Cheng JB et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-6.
248. Safko MJ, Chan SC, Cooper KD et al. Heterologous desensitisation of leukocytes: a possible mechanism for beta adrenergic blockade in atopic dermatitis. J Allergy Clin Immunol 1981; 68: 218-25.
249. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMPphosphodiesterase in atopic disease: a possible mechanism for cyclic AMPagonist hyporesponsiveness. J Allergy Clin Immunol 1982; 70: 452-7.
250. Sawai T, Ikai K, Uehara M. Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correlation with respiratory atopy. Br J Dermatol 1998; 138: 846-8.
251. Heskel NS, Chan SC, Thiel ML et al. Elevated umbilical-cord blood leukocyte cyclic adenosine-monophosphate phosphodiesterase activity in children with atopic parents. J Am Acad Dermatol 1984; 11: 422-6.
252. McMillan JC, Heskel NS, Hanifin JM. Cyclic AMP-phosphodiesterase activity and histamine-release in cord blood leukocyte preparations. Acta Derm Venereol (Stockh) 1985; 114: 24-32.
253. Holden CA, Chan SC, Hanifin JM. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J Invest Dermatol 1986; 87: 372-6.
254. Chan SC, Reifsnyder D, Beavo JA et al. Immunochemical characterization of the distinct monocyte cyclic amp-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 1993; 91: 1179-88.
255. Crocker IC, Ohia SE, Church MK. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. J Allergy Clin Immunol 1998; 102: 797-804.
256. Gantner F, Tenor H, Gekeler V et al. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 1997; 100: 527-35.
257. Li SH, Chan SC, Kramer SM et al. Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes. J Interferon Res 1993; 13: 197-202.
258. Spina D, Landells LJ, Page CP. The role of theophylline and phosphodiesterase 4 isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy 1998; 28: 24-34.
259. Cooper KD, Kang K, Chan SC et al. Phosphodiesterase inhibition by Ro20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 1985; 84: 477-82.
260. Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphatephosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol 1993; 100: 681-4.
261. Tenor H, Hatzelmann A, Church MK et al. Effects of theophylline and rolipram on leukotriene C-4 (LTC(4)) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996; 118: 1727-35.
262. Lidington E, Nohammer C, Dominguez M et al. Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors. Clin Exp Immunol 1996; 104: 66-71.
263. Essayan DM, Huang SK, Kageysobotka A et al. Effects of nonselective and isozyme-selective cyclic-nucleotide phosphodiesterase inhibitors on antigeninduced cytokine gene-expression in peripheral-blood mononuclear-cells. Am J Resp Cell Mol Biol 1995; 13: 692-702.
264. Coulson IH, Hurt GR, Holden CA. Inositol metabolism in mononuclear leucocytes from patients with atopic dermatitis. Br J Dermatol 1991; 124: 124-9.
265. Mallett RB, Myint S, Holden CA. Measurement of phosphoinositide-specific phospholipase C activity in mononuclear leucocytes from atopic and normal subjects. Br J Dermatol 1992; 127: 97-102.
266. Kanda N, Watanabe S. Intracellular 3',5'-adenosine cyclic monophosphate level regulates house dust mite-induced interleukin-13 production by T cells from mite-sensitive patients with atopic dermatitis. J Invest Dermatol 2001; 116: 3-11.
267. Gordon DJ, Ostlere LS, Holden CA. Neuropeptide modulation of Th1 and Th2 cytokines in peripheral blood mononuclear leucocytes in atopic dermatitis and non-atopic controls. Br J Dermatol 1997; 137: 921-7.
268. Anand P, Springall DR, Blank MA et al. Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhidrosis. Br J Dermatol 1991; 124: 547-9.
269. Giannetti A, Fantini F, Cimitan A et al. Vasoactive intestinal polypeptide and substance P in the pathogenesis of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 176: 90-2.
270. Pincelli C, Fantini F, Romualdi P et al. Skin levels of vasoactive intestinal polypeptide in atopic dermatitis. Arch Dermatol Res 1991; 283: 230-2.
271. Fantini F, Pincelli C, Romualdi P et al. Substance P levels are decreased in lesional skin of atopic dermatitis. Exp Dermatol 1992; 1: 127-8.
272. Pincelli C, Fantini F, Massimi P et al. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990; 122: 745-50.
273. Tobin D, Nabarro G, de la Faille HB et al. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992; 90: 613-22.
274. Coulson IH, Holden CA. Cutaneous reactions to substance P and histamine in atopic dermatitis. Br J Dermatol 1990; 122: 343-9.
275. Heyer G, Hornstein OP, Handwerker HO. Reactions to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. Acta Derm Venereol 1991; 71: 291-5.
276. Giannetti A, Girolomoni G. Skin reactivity to neuropeptides in atopic dermatitis. Br J Dermatol 1989; 121: 681-8.
277. Smith CH, Barker JN, Morris RW et al. Neuropeptides induce rapid expression of endothelial cell adhesion molecules and elicit granulocytic infiltration in human skin. J Immunol 1993; 151: 3274-82.
278. Kang H, Byun DG, Kim JW. Effects of substance P and vasoactive intestinal peptide on interferon-gamma and interleukin-4 production in severe atopic dermatitis. Ann Allergy Asthma Immunol 2000; 85: 227-32.
279. Wahlgren CF. Itch and atopic dermatitis: clinical and experimental studies. Acta Derm Venereol Suppl (Stockh) 1991; 165: 1-53.
280. Hernandez GL, Volpert OV, Iniguez MA et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001; 193: 607-20.
281. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002; 11: 12-24.
282. Stander S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44: 471-8.
283. Grando SA, Kist DA, Qi M et al. Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol 1993; 101: 32-6.
284. Heyer G, Vogelgsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic eczema. J Dermatol 1997; 24: 621-5.
285. Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritis caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989; 21: 135-6.
286. Metze D, Reimann S, Beissert S et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999; 41: 533-9.
287. Bernstein JE. Capsaicin in dermatologic disease. Semin Dermatol 1988; 7: 304-9.
288. Steinhoff M, Vergnolle N, Young SH et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000; 6: 151-8.
289. Cremer B, Heimann A, Dippel E et al. Pruritogenic effects of mitogen-stimulated peripheral blood mononuclear cells in atopic eczema. Acta Derm Venereol 1995; 75: 426-8.
290. Grothe C, Heese K, Meisinger C et al. Expression of interleukin-6 and its receptor in the sciatic nerve and cultured Schwann cells: relation to 18-kD fibroblast growth factor-2. Brain Res 2000; 885: 172-81.
291. Gaspari AA, Lotze MT, Rosenberg SA et al. Dermatologic changes associated with interleukin 2 administration. JAMA 1987; 258: 1624-9.
292. Dillon SR, Sprecher C, Hammond A et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-60.
293. Takaoka A, Arai I, Sugimoto M et al. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005; 516: 180-1.
294. Takaoka A, Arai I, Sugimoto M et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 2006; 15: 161-7.
295. Bilsborough J, Leung DY, Maurer M et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006; 117: 418-25.
296. Sonkoly E, Muller A, Lauerma AI et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-7.
297. Ostlere LS, Cowen T, Rustin MH. Neuropeptides in the skin of patients with atopic dermatitis. Clin Exp Dermatol 1995; 20: 462-7.
298. Kiistala R, Kiistala U, Parkkinen MU. Local cholinergic sweat stimulation in atopic dermatitis: an evaporimetric study. Acta Derm Venereol 1991; 71: 219-23.
299. Kiistala R. Cholinergic and adrenergic sweating in atopic dermatitis. Acta Derm Venereol 1992; 72: 106-8.
300. Kato F, Saga K, Morimoto Y et al. Pilocarpine-induced cholinergic sweat secretion compared with emotional sweat secretion in atopic dermatitis. Br J Dermatol 1999; 140: 1110-3.
301. Eishi K, Lee JB, Bae SJ et al. Impaired sweating function in adult atopic dermatitis: results of the quantitative sudomotor axon reflex test. Br J Dermatol 2002; 147: 683-8.
302. Kiistala R. Adrenaline-induced local sweating and vasoconstrictive responses in atopic skin. Br J Dermatol 1992; 126: 246-9.
303. Parkkinen MU, Kiistala R, Kiistala U. Sweating response to moderate thermal stress in atopic dermatitis. Br J Dermatol 1992; 126: 346-50.
304. Bothorel B, Heller A, Grosshans E et al. Thermal and sweating responses in normal and atopic subjects under internal and moderate external heat stress. Arch Dermatol Res 1992; 284: 135-40.
305. Hide M, Tanaka T, Yamamura Y et al. IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm Venereol 2002; 82: 335-40.
306. Buske-Kirschbaum A, Geiben A, Wermke C et al. Preliminary evidence for Herpes labialis recurrence following experimentally induced disgust. Psychother Psychosom 2001; 70: 86-91.
307. Arnetz BB, Fjellner B, Eneroth P et al. Stress and psoriasis: psychoendocrine and metabolic reactions in psoriatic patients during standardized stressor exposure. Psychosom Med 1985; 47: 528-41.
308. Buske-Kirschbaum A, Jobst S, Psych D et al. Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis. Psychosom Med 1997; 59: 419-26.
309. Buske-Kirschbaum A, Gierens A, Hollig H et al. Stress-induced immunomodulation is altered in patients with atopic dermatitis. J Neuroimmunol 2002; 129: 161-7.
310. Fjellner B, Arnetz BB, Eneroth P et al. Pruritus during standardized mental stress. Relationship to psychoneuroendocrine and metabolic parameters. Acta Derm Venereol 1985; 65: 199-205.
311. Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. Br J Dermatol 1991; 125: 59-61.
312. Rohleder N, Schommer NC, Hellhammer DH et al. Sex differences in glucocorticoid sensitivity of proinflammatory cytokine production after psychosocial stress. Psychosom Med 2001; 63: 966-72.
313. Aoki T, Fukuzumi J, Adachi K et al. Re-evaluation of skin lesion distribution in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 176: 19-23.
314. Colver GB, Mortimer PS, Millard PR et al. The 'dirty neck'-a reticulate pigmentation in atopics. Clin Exp Dermatol 1987; 12: 1-4.
315. Humphreys F, Spencer J, Mclaren K, Tidman MJ. An histological and ultrastructural study of the 'dirty neck' appearance in atopic eczema. Clin Exp Dermatol 1996; 21: 17-9.
316. Macharia WM, Anabwani GM, Owili DM. Clinical presentation of atopic dermatitis in Negroid children. Afr J Med Sci 1993; 22: 41-4.
317. Bannister MJ, Freeman S. Adult-onset atopic dermatitis. Australas J Dermatol 2000; 41: 225-8.
318. Waersted A, Hjorth N. Pityrosporum orbiculare-a pathogenetic factor in atopic dermatitis of the face, scalp and neck. Acta Derm Venereol Suppl (Stockh) 1985; 114: 46-8.
319. Rajka G. Essential Aspects of Atopic Dermatitis. Berlin: Springer-Verlag, 1989.
320. Simpson EL, Thompson MM, Hanifin JM. Prevalence and morphology of hand eczema in patients with atopic dermatitis. Dermatitis 2006; 17: 123-7.
321. Rystedt I. Atopy, hand eczema and contact dermatitis. Semin Dermatol 1986; 5: 290-300.
322. Diepgen T. Epidemiology and job-related problems for the eczema patient. Acta Derm Venereol 2005; 85 (Suppl.): 41-4.
323. Lee HJ, Ha SJ, Ahn WK et al. Clinical evaluation of atopic hand dermatitis. Pediatr Dermatol 2001; 18: 102-6.
324. Gustasson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis-a prospective follow-up to 7 years of age. Allergy 2000; 55: 240-5.
325. Ricci G, Patrizi A, Baldi E et al. Long-term follow up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol 2006; 55: 765-71.
326. Spergel JM, Mizoguchi E, Brewer JP et al. Epicutaneous sensitization with protein antigen induces localised allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998; 101: 1614-22.
327. Finlay AY, Nicholls S, King CS, Marks R. The dry non-eczematous skin associated with atopic eczema. Br J Dermatol 1980; 102: 249-56.
328. Uehara M. Clinical and histological features of dry skin in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114: 82-6.
329. Kim DW, Park JY, Na GY et al. Correlation of clinical features and skin barrier function in adolescent and adult patients with atopic dermatitis. Int J Dermatol 2006; 45: 698-701.
330. Chamlin SL, Frieden IJ, Fowler A et al. Ceramide-dominant barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001; 137: 1110-2.
331. Palmer CNA, Irvine DA, Terron-Kwiatkoski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
332. Yates VN, Kerr RA, MacKie RM. Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis-clinical features. Br J Dermatol 1983; 108: 633-8.
333. Podmore P, Burrows D, Eedy DJ et al. Seborrhoeic eczema-a disease entity or a clinical variant of atopic eczema? Br J Dermatol 1986; 115: 341-50.
334. Rysted I. Contact sensitivity in adults with atopic dermatitis in childhood. Contact Dermatitis 1985; 13: 1-8.
335. Heine G, Schnuch A, Uter W, Worm M. Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Allergy 2006; 61: 611-6.
336. Cronin E, McFadden JP. Patients with atopic eczema do become sensitised to contact allergens. Contact Dermatitis 1993; 28: 225-8.
337. Dooms-Goosens A, Morren M. Results of routine patch testing with corticosteroid series in 2073 patients. Contact Dermatitis 1992; 26: 182-91.
338. Hamann CP. Natural rubber latex protein sensitivity in review. Am J Contact Dermatitis 1993; 4: 4-21.
339. Holme SA, Lever RS. Latex allergy in atopic children. Br J Dermatol 1999; 140: 919-21.
340. Mäkelä L, Lammintausta K, Kalimo K. Contact sensitivity and atopic dermatitis: association with prognosis, a follow-up study in 801 atopic patients. Contact Dermatitis 2007; 56: 76-80.
341. Tada J, Toi Y, Akiyama H, Arata J. Infra-auricular fissures in atopic dermatitis. Acta Derm Venereol (Stockh) 1994; 74: 129-31.
342. Roupe G, Stannegard O. Anaphylactic shock elicited by topical administration of bacitracin. Arch Dermatol 1969; 100: 450-2.
343. Hansen KS, Petersen HO. Protein contact dermatitis in slaughterhouse workers. Contact Dermatitis 1989; 21: 221-4.
344. Hjorth N, Roed-Petersen J. Occupational protein contact dermatitis in food handlers. Contact Dermatitis 1976; 2: 28-42.
345. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45 (Suppl. 1): S67-8.
346. Lundberg L, Johannesson M, Silverdahl M et al. Health related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol (Stockh) 2000; 80: 430-4.
347. Holm EA, Esmann S, Jemec JBE. The handicap caused by atopic dermatitis-sick leave and job avoidance. J Eur Acad Dermatol Venereol 2006; 20: 255-9.
348. Lawson V, Lewis-Jones MS, Finlay AY et al. The family impact of childhood atopic dermatitis: the dermatitis family impact questionnaire. Br J Dermatol 1998; 138: 107-13.
349. Reid P, Lewis-Jones MS. Sleep difficulties and their management in pre-schoolers with atopic eczema. Clin Exp Dermatol 1995; 20: 38-41.
350. Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S et al. Sleep disturbances in children with atopic dermatitis. Arch Paediatr Adolesc Med 1995; 149: 856-60.
351. Beattie PE, Lewis-Jones MS. An audit of the impact of a consultation with a paediatric dermatology team on quality of life in infants with atopic eczema and their families: further validation of the Infants' Dermatitis Quality of Life Index and Dermatitis Family Impact score. Br J Dermatol 2006; 155: 1249-55.
352. Drake L, Prendergast M, Maher R et al. The impact of tacrolimus ointment on health-related quality of life of adult and paediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44 (Suppl. 1): S65-72.
353. Ellison JA, Patel L, Kecojevic T et al. Pattern of growth and adiposity from infancy to adulthood in atopic dermatitis. Br J Dermatol 2006; 155: 532-8.
354. Bode HH. Dwarfism following long-term corticosteroid therapy. JAMA 1980; 244: 813-4.
355. Patel L, Clayton PE, Addison GM et al. Linear growth in prepubertal children with atopic dermatitis. Arch Dis Child 1998; 79: 169-72.
356. Williams JV, Vowels B, Honig P, Leyden JJ. Staphylococcus aureus isolation from the lesions, the hands, and anterior nares of patients with atopic dermatitis. J Emerg Med 1999; 17: 207-11.
357. Rysted I, Stranegard IL, Stranegard O. Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol 1986; 114: 575-82.
358. Currie JM, Wright RC, Miller OG. The frequency of warts in atopic patients. Cutis 1971; 8: 243-5.
359. Williams H, Pottier A, Strachan D. Are viral warts seen more commonly in children with eczema? Arch Dermatol 1993; 129: 717-21.
360. Nahmia AJ, Foreschle JE, Feomino PM et al. Generalised eruption in a child with eczema due to Coxsackie virus A16. Arch Dermatol 1968; 97: 147-8.
361. Parkin JM, Eales LJ, Galazka AR et al. Atopic manifestation in the acquired immune deficiency syndrome: response to recombinant interferon-γ. BMJ 1987; 294: 1185-6.
362. Shohat M, Ben Amitai D, Shohat B et al. Atopic dermatitis and HTLV-1-associated myelopathy: associated or coincidental disorders? Dermatology 1999; 199: 356-60.
363. Sehgal VN, Jain S. Atopic dermatitis: ocular changes. Int J Dermatol 1994; 33: 11-4.
364. Uehara MAD. Infra-orbital fold in atopic dermatitis. Arch Dermatol 1981; 117: 627.
365. Williams HC, Pembroke AC. Infraorbital crease, ethnic group, and atopic dermatitis. Arch Dermatol 1996; 132: 51-4.
366. Karel I, Myska V, Koicalova E. Ophthalmological changes in atopic dermatitis. Acta Derm Venereol (Stockh) 1965; 45: 381-6.
367. Brunsting LA, Reed WB, Bair HL. Occurrence of cataracts and keratoconus with atopic dermatitis. Arch Dermatol 1955; 72: 237-41.
368. Copeman PWM. Eczema and keratoconus. BMJ 1966; ii: 977-9.
369. Nagaki Y, Hayasaka S, Kadoi C. Cataract progression in patients with atopic dermatitis. J Cataract Refract Surg 1999; 25: 96-9.
370. Matsuda A, Ebihara N, Kumagai N et al. Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Ophthalmol Vis Sci 2007; 48: 583-9.
371. Yoneda K, Okamoto H, Wada Y et al. Atopic retinal detachment. Report of four cases and review of the literature. Br J Dermatol 1995; 133: 586-91.
372. Hida T, Tano Y, Okinami N et al. Multicenter retrospective study of retinal detachment associated with atopic dermatitis. Jpn J Ophthalmol 2000; 44: 407-18.
373. Devlin J, Harrison CJ, Whitby DJ et al. Cartilaginous pseudo-cyst of the external auricle in children with atopic eczema. Br J Dermatol 1990; 122: 699-704.
374. Nassif A, Smith DL, Hanifin JM. Olecranon and pretibial bursitis in atopic dermatitis: coincidence or association? J Am Acad Dermatol 1994; 30: 737-42.
375. Van Haselen CW, Toonstra J, Preesman AH et al. Sezary syndrome in a young man with severe atopic dermatitis. Br J Dermatol 1999; 140: 704-7.
376. Laube S, Stephens M, Smith AG et al. Lymphomatoid papulosis in a patient with atopic eczema on long-term ciclosporin therapy. Br J Dermatol 2005; 152: 1346-8.
377. Wang H, Diepgen TL. Atopic dermatitis and cancer risk. Br J Dermatol 2006; 154: 205-10.
378. Musgrove K, Morgan JK. Infantile eczema. A long-term follow-up study. Br J Dermatol 1976; 95: 365-72.
379. Rajka G. Essential Aspects of Atopic Dermatitis. Berlin: Springer-Verlag, 1989.
380. Rystedt I. Prognostic factors in atopic dermatitis. Acta Derm Venereol (Stockh) 1985; 65: 206-13.
381. Sedlis E. Natural history of infantile eczema. Its incidence and course. J Pediatr 1965; 66: 158-63.
382. Vickers CFH. The natural history of atopic eczema. Acta Derm Venereol Suppl (Stockh) 1980; 92: 113-5.
383. Williams HC, Wüthrich B. The natural history of atopic dermatitis. In: Williams HC, ed. Atopic Dermatitis: The Epidemiology, Causes, and Prevention of Atopic Eczema. Cambridge: Cambridge University Press, 2000: 41-59.
384. Illi S, von Mutius E, Lau S et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004; 113: 925-31.
385. Sandström Falk MH, Faergemann J. Atopic dermatitis in adults: does it disappear with age? Acta Derm Venereol 2006; 86: 135-9.
386. Diepgen T. Epidemiology and job-related problems for the eczema patient. Acta Derm Venereol 2005; 85 (Suppl. 215): 41-4.
387. Yates VM, Kerr REI, MacKie RM. Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis I. Clinical features; 'total' and specific IgE levels. Br J Dermatol 1983; 108: 633-9.
388. Hodgson HJF, Davies RJ, Gent AE et al. Atopic disorders and adult coeliac disease. Lancet 1976; i: 115-7.
389. Warner JO, Norman AP, Soothill JF. Cystic fibrosis heterozygosity in the pathogenesis of allergy. Lancet 1976; i: 990-1.
390. Snyderman SE, Boyer A, Roitman E et al. The histidine requirement of the infant. Pediatrics 1963; 31: 786-801.
391. Frentz G, Everberg G, Wulf HC. Congenital perceptive hearing loss and atopic dermatitis. Acta Otolaryngol 1976; 82: 242.
392. Sandberg DH, McIntosh RM, Berstein CW. Severe steroid responsive nephrosis associated with hypersensitivity. Lancet 1977; i: 388-90.
393. Walley AJ, Chavanas S, Moffatt MF et al. Gene polymorphisms in Netherton and common atopic disease. Nat Genet 2001; 29: 175-8.
394. Williams J, Cahill J, Nixon R. Occupational autoeczematization or atopic eczema precipitated by occupational contact dermatitis? Contact Derm 2007; 56: 21-6.
395. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev 2005; 203: 244-50.
396. Grimbacher B, Holland SM, Gallin JL et al. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder. N Engl J Med 1999; 340: 692-702.
397. Renner ED, Puck JM, Holland SM et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr 2004; 144: 93-9.
398. Fletcher S, Bain B. Diagnosis and treatment of hypereosinophilic syndromes. Curr Opin Hematol 2007; 14: 37-42.
399. Dagmar S, Hans-Uwe S. Eosinophilic disorders. J Allergy Clin Immunol 2007; 119: 1291-9.
400. Kazmieruwski JA, Chusie MJ, Parrillo JE et al. Dermatologic manifestations of the hypereosinophilia syndrome. Arch Dermatol 1978; 114: 531-5.
401. Leiferman KM. Hypereosinophilic syndrome. Semin Dermatol 1995; 14: 122-8.
402. Offidani A, Bernadini ML, Simonetti O et al. Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome. Br J Dermatol 2000; 143: 675-7.
403. Nir MA, Westfried M. Hypereosinophilic dermatitis. A distinct manifestation of the hypereosinophilic syndrome with response to dapsone. Dermatologica 1981; 162: 444-50.
404. Jacyk WK, Simson IW, Slater DN, Leiferman KM. Pachydermatous eosinophilic dermatitis. Br J Dermatol 1996; 134: 469-74.
405. Juhlin L, Johansson SGO, Bennick H et al. Immunoglobulin E in dermatoses. Arch Dermatol 1969; 100: 12-16.
406. David TJ. Conventional allergy tests. Arch Dis Child 1991; 66: 281-2.
407. Pryzbilla B, Ring J. Food allergy and atopic eczema. Semin Dermatol 1990; 9: 220-5.
408. Darsow U, Ring J. Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests. Clin Exp Dermatol 2000; 25: 544-51.
409. Hanifin JM. Atopic dermatitis in infants and children. Pediatr Clin North Am 1991; 38: 763-89.
410. Patrizi A, Guerrini V, Ricci G et al. The natural history of sensitizations to food and aeroallergens in atopic dermatitis: a 4-year follow-up. Pediatr Dermatol 2000; 17: 261-5.
411. Sandström Falk MH, Tengvall Linder M, Johansson C et al. The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol 2005; 85: 17-23.
412. Cronin E, McFadden JP. Patients with atopic eczema do become sensitised to contact allergens. Contact Dermatitis 1993; 28: 225-8.
413. Lever R, Forsyth A. Allergic contact dermatitis in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992; 76: 95-8.
414. Niggemann B. The role of the atopy patch test (APT) in diagnosis of food allergy in infants and children with atopic dermatitis. Pediatr Allergy Immunol 2001; 12: 37-40.
415. Oranje AP, Vangysez D, Mulder PGH, Dieges PH. Food-induced contact urticaria syndrome (CUS) in atopic dermatitis: reproducibility of repeated and duplicate testing with a skin provocation test, the skin application food test (SAFT). Contact Dermatitis 1994; 31: 314-8.
416. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1-191.
417. Darsow U, Lubbe J, Taïeb A et al. for the European Task Force on Atopic Dermatitis. Position paper on the diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005; 19: 286-95.
418. National Institute for Health and Clinical Excellence. Atopic Eczema in Children: management of atopic eczema in children from birth up to the age of 12 years, 2007. http://www.nice.org.uk/Guidance/CG57
419. Brown S, Reynolds NJ. Atopic and non-atopic eczema. BMJ 2006; 332: 584-8.
420. Hanifin JM, Cooper KD, Ho VC et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/ American Academy of Dermatology Association. Administrative regulations for evidence based clinical practice guidelines. J Am Acad Dermatol 2004; 50: 391-404.
421. Shum KW, Lawton S, Williams HC et al. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 3: audit of service outcome. Br J Dermatol 2000; 142: 721-7.
422. Kawashima M, Harada S. Effect of standard medication on quality of life of patients with atopic dermatitis. J Dermatol 2007; 34: 9-16.
423. Callen J, Chamlin S, Eichenfield LF et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156: 203-21.
424. Krejci Manwaring J, Tusa MG, Carrol C et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007; 56: 211-6.
425. Staab D, Diepgen TL, Fartasch M et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomized controlled trial. BMJ 2006; 332: 933-8.
426. Holden CA, English J, Hoare C et al. Advised best practice for the use of emollients in eczema and other dry skin conditions. J Dermatol Treat 2002; 13: 103-6.
427. Buske-Kirschbaum A, Geiben A, Hellhammer D. Psychobiological aspects of atopic dermatitis: an overview. Psychother Psychosom 2001; 70: 6-16.
428. Linnet J, Jemec GB. The assessment of anxiety and dermatological life quality in patients with atopic dematitis. Br J Dermatol 1999; 140: 268-72.
429. Staughton R. Psychologic approach to atopic skin disease. J Am Acad Dermatol 2001; 45 (Suppl. 1): S53-4.
430. Loden M, Andersson A-C. Effect of topically applied lipids on surfactant irritated skin. Br J Dermatol 1996; 134: 215-20.
431. Grimalt R, Mengeaud V, Cambazard F. The steroid sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology (Basel) 2007; 214: 61-7.
432. Chamlin SL, Frieden IJ, Fowler A et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001; 137: 1110-2.
433. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6.
434. Thomas KS, Armstrong S, Avery A et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild to moderate atopic eczema. BMJ 2002; 324: 768-71.
435. Long CC, Finlay AY. The finger tip unit-a new practical measure. Clin Exp Dermatol 1991; 16: 444-7.
436. Cubey RB. Glaucoma following the application of corticosteroids to the skin of the eyelids. Br J Dermatol 1976; 95: 207-8.
437. Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol 1999; 26: 770-9.
438. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135: 1522-5.
439. Kemp JP. Tolerance to antihistamines: is it a problem? Ann Allergy 1989; 63: 621-3.
440. Diepgen TL. Early treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double- blind, placebo-controlled trial (the ETAC trial) over 18 months. Paediatr Allergy Immunol 2002; 13: 278-86.
441. Hung SH, Lin YT, Chu CY et al. Staphylococcus colonisation in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol 2007; 98: 51-6.
442. Breneman DL, Hanifin JM, Berge CA et al. The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis 2000; 66: 296-300.
443. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528-37.
444. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone proprionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis patients: randomized, double-blind, parallel group study. BMJ 2003; 326: 1367.
445. Wahn U, Bos JD, Goodfield M et al. Flare reduction in eczema with Elidel. (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
446. Nakahara T, Koga T, Fukagawa S et al. Intermittent topical corticosteroid/ tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004; 31: 524-8.
447. Schmitt J, Heese E, Wozel G, Meurer M. Effectiveness of inpatient treatment on quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris. Dermatology (Basel) 2007; 214: 68-76.
448. Devillers ACA, Oranje AP. Efficacy and safety of 'wet wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006; 154: 579-85.
449. Ashcroft DM, Dimmock P, Garside R et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: metaanalysis of randomized controlled trials. BMJ 2005; 330: 516-22.
450. Luger TA, Lahfa M, Folster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004; 15: 169.
451. Shainhouse T, Eichenfield LF. Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. Expert Opin Drug Saf 2003; 2: 457-65.
452. Arellano FM, Wentworth CE, Arana A et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-16.
453. Spergel JM, Leung DYM. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006; 6: 270-4.
454. Schmidt-Grendelmeier P, Simon D, Simon H-U et al. Epidemiology, clinical features, and immunology of the 'intrinsic' type (non-IgE-mediated) of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56: 841-9.
455. Société Francaise de Dermatolgie. Consensus conference; management of atopic dermatitis in children. Recommendations (short version). Eur J Dermatol 2005; 15: 215-23.
456. Lever R. The role of food in atopic eczema. J Am Acad Dermatol 2001; 45 (Suppl. 1): S57-60.
457. Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107: 669-75.
458. Atherton DJ, Sewell M, Soothill JF et al. A double-blind controlled crossover trial of an antigenic avoidance diet in atopic eczema. Lancet 1978; i: 401-3.
459. Lever R, MacDonald C, Waugh P, Aitchison T. Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol 1998; 9: 13-9.
460. Sampson H. The evaluation and management of food allergy in atopic dermatitis. Clin Dermatol 2003; 21: 183-92.
461. David T. Anaphylactic shock during elimination diets for severe atopic eczema. Arch Dis Child 1984; 59: 983-6.
462. Niggemann B, Binder C, Dupont C et al. Prospective, controlled, multi-center study on the effect of an amino-acid-based formula in infants with cows milk allergy/intolerance and atopic dermatitis. Pediatr Allergy Immunol 2001; 12: 78-82.
463. Gdalevich M, Mimouni D, David M, Mimouni M. Breast-feeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. J Am Acad Dermatol 2001; 45: 520-7.
464. Neild VS, Marsden RA, Bailes JA, Bland JM. Egg and milk exclusion diets in atopic eczema. Br J Dermatol 1986; 114: 117-23.
465. Worm M, Ehlers I, Sterry W, Zuberbier T. Clinical relevence of food additives in adult patients with atopic dermatitis. Clin Exp Allergy 2000; 30: 407-14.
466. Rajka G. Essential Aspects of Atopic Dermatitis. Berlin: Springer-Verlag, 1989: 80.
467. Friedmann PS. Dust mite avoidance in atopic dermatitis. Clin Exp Dermatol 1999; 24: 433-7.
468. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of house dust mite allergen avoidance in atopic dermatitis. Lancet 1996; 347: 15-8.
469. Ricci G, Patrizi A, Specchia F et al. Effect of house dust mite avoidance measures in children with atopic dermatitis. Br J Dermatol 2000; 143: 379-84.
470. Gutgesell C, Heise S, Seubert S et al. Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis. Br J Dermatol 2001; 145: 70-4.
471. Hide DW, Matthews S, Tariq S, Arshad SH. Allergen avoidence in infancy and allergy at four years of age. Allergy 1996; 51: 89-93.
472. Shaw DW, Maibach HI, Eichenfield LF. Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy. J Am Acad Dermatol 2007; 56: 342-5.
473. Ockenfels HM, Seemann U, Goos M. Contact allergy in patients with periorbital eczema: an analysis of allergens. Data recorded by the information network of the Departments of Dermatology. Dermatology 1997; 195: 119-24.
474. Roul S, Ducombs G, Taieb A. Usefulness of the European standard series for patch testing in children. A 3-year single-centre study of 337 patients. Contact Dermatitis 1999; 40: 232-5.
475. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol 2000; 25: 552-8.
476. Reynolds NJ, Franklin V, Gray JC et al. Narrow-band ultraviolet B and broadband ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357: 2012-6.
477. Tzaneva S, Seeber A, Schwaiger M et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001; 45: 503-7.
478. Der-Petrossian M, Seeber A, Honigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol 2000; 142: 39-43.
479. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol 2007; 32: 28-33.
480. George S, Bilsand D, Johnson BE et al. Narrow-band UVB (TL-01) airconditioned therapy for chronic severe adult atopic eczema. Acta Derm Venereol Suppl (Stockh) 1992; 176: 137-8.
481. Berth-Jones J, Graham-Brown RAC, Marks R et al. Long term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997; 136: 76-81.
482. Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52-8.
483. Harper JI, Berth-Jones J, Camp RD et al. Cyclosporin for atopic dermatitis in children. Dermatology 2001; 203: 3-6.
484. Sepp N, Fritsch PO. Can cyclosporin A induce permanent remission of atopic dermatitis? Br J Dermatol 1993; 128: 213-6.
485. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002; 147: 308-15.
486. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a doubleblind, randomized controlled trial. Lancet 2006; 367: 839-46.
487. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, doseranging study of methotrexate for moderate-to-severe adult atopic dermatitis. Br J Dermatol 2007; 156: 346-51.
488. Goujon C, Bérard F, Dahel K et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16: 155-8.
489. Grundmann-Kollmann M, Podda M, Ochsendorf F et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137: 870-3.
490. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007; 32: 23-7.
491. Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol 2006; 142: 555-8.
492. Lane JE, Cheyney JM, Lane TN et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-72.
493. Buka RL, Resh B, Roberts B et al. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005; 53: 358-9.
494. Ricci G, Patrizi A, Bellini F, Medri M. Use of textiles in atopic dermatitis: care of atopic dermatitis. Curr Probl Dermatol 2006; 33: 127-43.
495. Senti G, Steinmann LS, Fischer B et al. Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment. Dermatology 2006; 213: 228-33.
496. Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy 2006; 61: 431-7.
497. Fölster HR, Müller F, Schnopp N et al. Prospective, randomised controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155: 1256-61.
498. Kimata H. Improvement of atopic dermatitis and reduction of skin allergic responses by oral intake of konjac ceramide. Pediatr Dermatol 2006; 23: 386-9.
499. Morse PF, Horrobin DF, Manku MS et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema: relationship between plasma essential fatty acid changes and clinical response. Br J Dermatol 1989; 121: 75-90.
500. Williams HC. Evening primrose oil for atopic dermatitis-time to say goodnight. BMJ 2003; 327: 1358-9.
501. Sheehan M, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992; 126: 179-84.
502. Sheehan M, Rustin MHA, Atherton DJ et al. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis: results of a double-blind placebocontrolled study. Lancet 1992; 340: 13-7.
503. Graham-Brown R. Toxicity of Chinese herbal remedies. Lancet 1992; 340: 673.
504. Businco L, Cantani A. Mast cell blockers and atopic eczema. In: Ruzicka T, Ring J, Pryzbilla B, eds. Handbook of Atopic Eczema. Berlin: Springer-Verlag, 1991: 407-14.
505. Kimata H, Hirasuka S. Effect of topical cromoglycate solution on atopic dermatitis: combined treatment of sodium cromoglycate solution with the oral anti-allergic medication oxotamide. Eur J Pediatr 1994; 153: 66-71.
506. Boguniewicz M, Jaffe HS, Izu A et al. Recombinant gamma-interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990; 88: 365-70.
507. Leung DY, Hirsch RL, Scheider L et al. Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol 1990; 85: 927-33.
508. Hanifin JM, Chan CS, Cheng JB et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107: 51-6.
509. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002; 27: 3-7.
510. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo P. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001; 56: 512-7.
511. Capella GL, Grigerio E, Altomare G. A randomised trial of leukotriene receptor antagonist monteleukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001; 11: 209-13.
512. Prinz B, Michelsen S, Pfeiffer C, Plewig G. Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999; 40: 577-82.
513. Glover MT, Atherton DJ. A doubleblind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22: 440-6.
514. Werfel T, Breuer K, Ruéff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multicentre, randomised, dose-response study. Allergy 2006; 61: 202-5.
515. Mastrandrea F. Immunotherapy in atopic dermatitis. Expert Opin Investig Drugs 2001; 10: 49-63.
516. Simpson EL, Hanifin JM. Atopic dermatitis. Med Clin N Am 2006; 90: 149-67.
517. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess 2000; 4: 16-20.
518. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy and/or lactation for preventing or treating atopic disease in the child. Cochrane Database of Systematic Reviews, Issue 4, Chichester (UK): John Wiley and Sons, 2004.
519. Fergusson DM, Horwood LJ. Early solid food diet and eczema in childhood: a 10-year longitudinal study. Pediatr Allergy Immunol 1994; 5 (Suppl. 1): 44-7.
520. Hanifin JM, Cooper KD, Ho VC et al. Guidelines for care for atopic dermatitis. J Am Acad Dermatol 2004; 50: 391-404.
521. Osborn DA, Sinn J. Formulas containing hydrolysed protein for prevention of allergy and food intolerance in infants. Cochrane Database of Systematic Reviews, Issue 1, Chichester (UK): John Wiley and Sons, 2004.
522. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high risk children: a randomized controlled trial. J Allergy Clin Immunol 2007; 119: 184-91.
523. Diepgen T. Epidemiology and job-related problems for the eczema patient. Acta Derm Venereol 2005; 85 (Suppl.): 41-4.